Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
Type
Public
HQ
Cambridge, US
Founded
1978
Size (employees)
7,300 (est)-1%
Website
biogen.com
Biogen was founded in 1978 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

CEO
Susan Alexander

Susan Alexander

EVP
Jeffrey Capello

Jeffrey Capello

EVP
Michael Ehlers

Michael Ehlers

EVP
Ginger Gregory

Ginger Gregory

EVP
Chirfi Guindo

Chirfi Guindo

EVP
Show more

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Show all (1)
Report incorrect company information

Biogen Financials and Metrics

Biogen Financials

Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
USD

Revenue (Q1, 2017)

2.8 b

Net income (Q1, 2017)

747.5 m

EBIT (Q1, 2017)

1 b

Market capitalization (14-Jun-2018)

64.5 b

Closing share price (14-Jun-2018)

305.7

Cash (31-Mar-2017)

924 m
Biogen's current market capitalization is $64.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9 b9.7 b10.8 b11.4 b

Revenue growth, %

40%11%6%

General and administrative expense

1.9 b

R&D expense

2 b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

General and administrative expense

576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

R&D expense

447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

Operating expense total

1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b

Inventories

659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

Accounts Receivable

1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Current Assets

3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Inventories

(240 m)(190 m)(170 m)(165.6 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

Inventories

865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Accounts Payable

282.7 m251.2 m271.3 m225.9 m274 m316.4 m
USDY, 2017

Revenue/Employee

379.8 k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
FY, 2016

Phase I Trials Products

4

Phase II Trials Products

10

Phase III Trials Products

2

Training Provided, no. of people

40 k
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Karyopharm Therapeutics January 25, 2018$10 m
Report incorrect company information

Biogen Online and Social Media Presence

Embed Graph
Report incorrect company information

Biogen News and Updates

Now that Ironwood's spinning off R&D, activist Alex Denner is easing up

Ironwood’s activist investor likes what it’s seen recently from the Massachusetts drugmaker—so much so that Sarissa Capital held off on pushing for a spot on the company's board. What's to like? Ironwood's plan to split into two companies, one focused mostly on marketed meds, the other on pipeline.

Biogen poaches Pfizer dealmaker Dan Karp for stepped-up M&A push

Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it recruited veteran Dan Karp in a revamp of its BD and corporate strategy team.

Pemphigus Vulgaris -Therapeutics Development in depth with Future Prospects by Leading Key Players: Biogen Inc, HanAll Biopharma, Immunomedics

Pemphigus Vulgaris -Therapeutics Development by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information